Evidence from Human Genome Research on Anti-Innovation Effects of Patents

From P2P Foundation
Revision as of 05:55, 17 July 2015 by Mbauwens (talk | contribs) (Created page with " '''* Paper: Intellectual property rights and innovation: Evidence from the human genome. Heidi Williams, December 30, 2009''' URL = http://lasindias.com/gomi/Williams_jmp.pd...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

* Paper: Intellectual property rights and innovation: Evidence from the human genome. Heidi Williams, December 30, 2009

URL = http://lasindias.com/gomi/Williams_jmp.pdf

Abstract

"This paper provides empirical evidence on how intellectual property (IP) on a given technology affects subsequent innovation. To shed light on this question, I analyze the sequencing of the human genome by the public Human Genome Project and the private firm Celera, and estimate the impact of Celera’s gene-level IP on subsequent scientific research and product development outcomes. Celera’s IP applied to genes sequenced first by Celera, and was removed when the public effort re-sequenced those genes. I test whether genes that ever had Celera’s IP differ in subsequent innovation, as of 2009, from genes sequenced by the public effort over the same time period, a comparison group that appears balanced on ex ante genelevel observables. A complementary panel analysis traces the effects of removal of Celera’s IP on within-gene flow measures of subsequent innovation. Both analyses suggest Celera’s IP led to reductions in subsequent scientific research and product development outcomes on the order of 30 percent. Celera’s short-term IP thus appears to have had persistent negative effects on subsequent innovation relative to a counterfactual of Celera genes having always been in the public domain."